Figure 1
Figure 2
Results of univariable logistic regression analysis for prediction of improved quality of life, as assessed by Short Form-36 Health Survey_ P-value<0_1 is considered significant_
| Variable | OR | 95% CI | p-value | |
|---|---|---|---|---|
| Lower | Upper | |||
| Baseline characteristics | ||||
| Age, years | 0.978 | 0.925 | 1.033 | 0.424 |
| Gender | 0.556 | 0.159 | 1.938 | 0.356 |
| BMI | 1.119 | 0.987 | 1.269 | 0.080 |
| STEMI at admission | 0.500 | 0.131 | 1.905 | 0.310 |
| LVEF<50% | 5.863 | 1.441 | 23.851 | 0.013 |
| CV risk factors | ||||
| Arterial hypertension | 1.067 | 0.364 | 3.128 | 0.906 |
| Diabetes mellitus | 1.474 | 0.424 | 5.121 | 0.542 |
| Dyslipidaemia | 2.917 | 0.914 | 9.309 | 0.071 |
| Smoking | 0.875 | 0.306 | 2.504 | 0.803 |
| Laboratory parameters | ||||
| Creatinine | 1.328 | 0.150 | 11.771 | 0.799 |
| Hb | 1.221 | 0.799 | 1.865 | 0.356 |
| LDL-C | 0.999 | 0.984 | 1.013 | 0.873 |
| NT-proBNP | 1.000 | 1.000 | 1.000 | 0.976 |
| Plt count | 0.996 | 0.988 | 1.005 | 0.389 |
| TnI | 1.003 | 0.996 | 1.010 | 0.425 |
| Pharmacotherapy at discharge | ||||
| Aspirin | 0.959 | 0.867 | 1.014 | 0.593 |
| P2Y12 inhibitor | 1.320 | 0.833 | 2.093 | 0.238 |
| Statin | 0.998 | 0.990 | 1.006 | 0.551 |
| β-blocker | 3.846 | 0.402 | 36.822 | 0.243 |
| ACE-inhibitor or ARB | 0.862 | 0.051 | 14.506 | 0.918 |
| Diuretics | 1.474 | 0.424 | 5.121 | 0.542 |
| Aldosterone antagonists | 0.825 | 0.244 | 2.793 | 0.757 |
| Cardiac rehabilitation – number (%) | 1.010 | 0.986 | 1.034 | 0.432 |
Results of multivariable logistic regression analysis for prediction of improved quality of life (QOL) 6 months after AMI, as assessed by Short Form-36 Health Survey, including explanatory factors which significantly differed between patients with and without improved QOL and which were predictors of improved QOL in univariate analysis_
| Variable | OR | 95% CI | p-value | |
|---|---|---|---|---|
| Lower | Upper | |||
| BMI | 1.096 | 0.958 | 1.255 | 0.180 |
| Dyslipidaemia | 1.921 | 0.544 | 6.786 | 0.310 |
| EF<50% | 4.463 | 1.045 | 19.059 | 0.043 |
Eligibility criteria for the study evaluating the health-related quality of life after first-time acute myocardial infarction in Poland_
| Inclusion criteria | Exclusion criteria |
|---|---|
| • Age ≥ 18 years | • Cardiogenic shock |
| • Informed consent to participate in the study | • Severe chronic renal failure |
| • First ST-elevation myocardial infarction (STEMI) or non-STEMI | (eGFR<30 mL/min) |
| • PCI with stent implantation | • Severe liver insufficiency (Child-Pugh C) |
| • Capability to fill-in the quality-of-life questionnaires alone or under supervision | • Autoimmune disease |
| • Active neoplasm | |
| • Known pregnancy, breast-feeding, or intention to | |
| become pregnant during the study period |
Comparison of baseline characteristics between patients with improved and without improved health-related quality of life, as assessed by Short Form-36 Health Survey_ P-value<0_05 is considered significant_
| Inclusion criteria | All patients (n=56) | QoL improved (n=26) | QoL not improved (n=30) | p | |||
|---|---|---|---|---|---|---|---|
| Characteristic | |||||||
| Age, years – mean (SD) | 64.3 | 9.7 | 63.2 | 8.6 | 65.2 | 10.7 | 0.593 |
| Male gender – n (%) | 42 | 75% | 21 | 80% | 21 | 70% | 0.353 |
| BMI – n (range) | 28.5 | 20.3-30.2 | 29.0 | 20.0-34.7 | 27.1 | 20.3-30.2 | 0.046 |
| STEMI at admission – n (%) | 44 | 79% | 22 | 84% | 22 | 73% | 0.305 |
| LVEF, % – median (range) | 52 | 27-68 | 50 | 27-58 | 55 | 35-68 | 0.013 |
| CV risk factors – n (%) | |||||||
| Arterial hypertension | 34 | 61% | 16 | 0.62% | 18 | 60% | 0.906 |
| Diabetes mellitus | 13 | 23% | 7 | 27% | 6 | 20% | 0.541 |
| Dyslipidaemia | 36 | 64% | 20 | 76% | 16 | 53% | 0.046 |
| Smoking | 29 | 52% | 13 | 50% | 16 | 53% | 0.803 |
| Laboratory parameters | |||||||
| Creatinine, mg/dl – median (range) | 0.95 | 0.33-1.65 | 0.94 | 0.55-1.51 | 0.95 | 0.33-1.65 | 0.966 |
| Hb, g/dl – median (range) | 13.8 | 10.2-17.5 | 13.9 | 11.3-17.5 | 13.9 | 10.2-16.0 | 0.698 |
| LDL-C – median (range) | 122 | 53-218 | 124 | 69-197 | 122 | 65-218 | 0.928 |
| NT-proBNP – median (range) | 764 | 127-12708 | 962 | 146-4942 | 386 | 127-12708 | 0.153 |
| Plt count, 103/μl – median (range) | 230 | 111-453 | 236 | 131-352 | 230 | 172-281 | 0.533 |
| TnI, ng/ml – median (range) | 13.0 | 0.4-685 | 20.3 | 0.5-685 | 11.4 | 0.4-236 | 0.457 |
| Pharmacotherapy at discharge – number (%) | |||||||
| Aspirin | 56 | 100% | 26 | 100% | 30 | 100% | 1.000 |
| P2Y12 inhibitor | 56 | 100% | 26 | 100% | 30 | 100% | 1.000 |
| Statin | 56 | 100% | 26 | 100% | 30 | 100% | 1.000 |
| β-blocker | 51 | 91% | 25 | 96% | 26 | 87% | 0.214 |
| ACE-inhibitor or ARB | 54 | 96% | 25 | 96% | 29 | 97% | 0.918 |
| Diuretics | 13 | 23% | 7 | 27% | 6 | 20% | 0.541 |
| Aldosterone antagonists | 14 | 25% | 6 | 23% | 8 | 27% | 0.757 |
| Cardiac rehabilitation – number (%) | 44 | 79% | 22 | 84% | 22 | 73% | 0.305 |